It’s not a good day for the ASX-listed medical imaging company.
The post Mach7 (ASX:M7T) share price stumbles 8% on business update appeared first on The Motley Fool Australia. –
The Mach7 Technologies Ltd (ASX: M7T) share price has taken a tumble in today’s trading session.
Shares in the medical imaging software company have taken a dive after Mach7 released its financial report for the fourth quarter and FY21.
Let’s take a look at how Mach7 performed.
Mach7 reports back-to-back annual profits
Earlier today, Mach7 released its activities report for the fourth quarter and overall FY21.
The company’s report highlighted Mach7 recording its highest ever cash receipts. The company recorded a 23% growth in cash receipts over the prior year to $21 million.
As a result, Mach7 reported its second consecutive year of positive operating cashflows. For FY21, the company reported positive operating cash of $1.2 million.
In addition, Mach7 recorded its highest annual sales on record. The company reported a 95% increase in sales to $25.64 million in FY21, bringing the company’s customer count to 165.
Mach7 also reported low customer churn, less than 2% for the financial year.
The company also underscored its strong financial position, with Mach7 finishing the year with $18.36 million cash on hand.
Overall, Mach7 expects annual revenue to be in the range of $19 million and $19.5 million. The company noted it will release its audited annual financial report in August.
Looking ahead to FY22, Mach7 expects to see strong double-digit revenue growth (higher than 15%) on FY21’s figure.
More on Mach7’s performance
Mach7 develops innovative data management solutions for healthcare institutions. The company’s revenue is generated through live annual support contracts and monthly subscriptions.
In today’s report, Mach7 noted the company is now generating $13.36 million of annual recurring revenue (ARR). The company said its ARR has more than doubled since the previous year where Mach7 reported an ARR of $6.51 million.
In addition, Mach7 noted that ARR will continue to grow as existing customers become fully deployed and new customers license the software.
Mach7 signed several new sales orders, contracts, and contract renewals during the fourth quarter of FY21.
Just yesterday, Mach7 also announced an expansion order from Advocate Aurora Healthcare valued at $4.3 million over 5 years. But it seems investors aren’t enthused by today’s news.
Snapshot of the Mach7 share price
Despite starting the year relatively strongly, the Mach7 share price has floundered in 2021. Since the start of the year, shares in Mach7 are down 28%.
At the time of writing, the Mach7 share price is trading more than 5% lower for the day at around 91 cents. Shares in the company hit an intra-day low of 87.5 cents earlier, to be down more than 8% for the day.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of May 24th 2021
Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended MACH7 FPO. The Motley Fool Australia has recommended MACH7 FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.